Opinion|Videos|April 1, 2026
Navigating Second-Line Treatment Decisions in EGFR+ NSCLC
Author(s)Christine M. Lovly, MD, PhD, Matthew Lee, MD
Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss second-line treatment approaches and sequencing considerations in EGFR-mutated non–small cell lung cancer.
Advertisement
Episodes in this series
Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss evolving strategies for second-line treatment in EGFR-mutated non–small cell lung cancer. Lovly reviews how resistance mechanisms and prior therapy exposure guide treatment selection, including the use of targeted agents and antibody-drug conjugates. Lee underscores the importance of integrating emerging data from phase 3 trials such as MARIPOSA-2 (NCT04988295) and PALOMA-3 (NCT05388669) to refine sequencing decisions.
Advertisement
Related to this article
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
CHMP has recommended EU approval of senaparib for advanced ovarian cancer based on FLAMES data.
The CHMP recommended perioperative pembrolizumab plus enfortumab vedotin for resectable muscle-invasive bladder cancer.
The FDA approved imlunestrant/abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after progression on endocrine therapy.
Roswell Park Comprehensive Cancer Center unveiled a new and more compact mobile lung cancer screening unit.
The CHMP recommended approval of adjuvant T-DXd for HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy.
Udai S. Kammula, MD, FACS, discusses TIL therapy outcomes, the UMIS biomarker, and treatment implications in metastatic uveal melanoma.
CHMP has recommended EU marketing authorization for relacorilant combined with nab-paclitaxel in platinum-resistant ovarian cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Imlunestrant Plus Abemaciclib for ER+, HER2–, ESR1-Mutated Metastatic Breast Cancer
2
CHMP Recommends Label Expansion of Melflufen to Third-Line Lenalidomide-Refractory Multiple Myeloma
3
Phase 1 Data Support DAWN-303’s Evaluation of INCB161734 in Frontline KRAS G12D–Mutated PDAC
4
Tumor-Reactive TIL and UMIS Biomarker Predict Response in Metastatic Uveal Melanoma
5